AceLink Therapeutics to Present at World Orphan Drug Congress USA
NEWARK, Calif.--(BUSINESS WIRE)--AceLink Therapeutics, Inc., a clinical stage biopharmaceutical company developing the next generation of oral substrate reduction therapies (SRTs) to address significant unmet medical needs and improve the quality of life of patients with inherited disorders of glycosphingolipid metabolism, today announced that Jerry Shen, Ph.D., Chief Executive Officer and...
